When a Medical Product Is a Drug and a Device at Once

Some of the most important products in modern medicine refuse to sit in a single category. A prefilled syringe, a drug-eluting stent, an inhaler, an insulin pen, a transdermal patch: each is part device and part drug or biologic, and each has to answer to more than one set of regulatory expectations. These combination products are a growing share of what companies bring to market, and they're also among the hardest to navigate, because the regulatory system was built around cleaner categories than the ones innovation keeps producing.

When a Product Doesn't Fit One Box

The trouble starts with classification. A conventional drug and a conventional device travel well-worn paths, but a product that meaningfully combines both doesn't belong entirely to either. That ambiguity isn't a minor labeling issue. It determines what evidence a company must generate, which requirements apply, and how the whole review will be structured. Teams that assume their product is simply a device with a drug attached, or a drug in a fancy delivery system, often discover too late that the reality is more tangled and the obligations more demanding than they planned for. Getting the classification honest and early is the foundation everything else rests on.

Where Specialized Guidance Pays Off

This is the kind of terrain where experienced help earns its cost quickly, because so much of the difficulty lies in knowing how the pieces fit together before you've learned it the hard way. Engaging FDA consulting with genuine combination-product experience gives you a team of experts who have navigated the overlapping requirements and jurisdictional questions before and can map the path while the plan is still flexible. Advisors who have done this work understand where the two regulatory worlds collide and how to satisfy both without duplicating effort or leaving gaps. Against the cost of a stalled program or a misclassified product, that expertise is almost always the smaller number.

Primary Mode of Action Decides Who Leads

A central question for any combination product is which component does the primary therapeutic work, because that answer shapes how the product is reviewed. When a product's main effect comes from its drug component, the review is led differently than when the device component drives the outcome. The agency assigns a lead review center based on that primary mode of action, and the assignment influences timelines, evidence expectations, and the entire character of the process. Misjudging which component is primary can send a company down the wrong preparatory path, generating the wrong kind of evidence for the review it will actually face.

One Product, Multiple Rulebooks

The defining challenge of a combination product is that its parts are regulated under different frameworks that don't dissolve just because the components are packaged together. Combination products are formally defined in federal regulation, and the framework laid out in the Code of Federal Regulations makes clear that a sponsor generally has to satisfy the requirements applying to each constituent part, not just one of them. In practice that means a company may need to meet device quality-system expectations and drug or biologic requirements at the same time, coordinating obligations that were never designed to be met in tandem. That dual burden is exactly where under-prepared teams stall.

Devices Carry Their Own Complexity

Even setting the drug side aside, the device component of a combination product brings its own layered requirements. Devices are themselves risk-classified, with dramatically different expectations depending on where a product lands, from relatively streamlined routes for lower-risk devices to demanding, evidence-heavy pathways for higher-risk ones. Design controls, quality systems, and human-factors considerations all attach to the device element and don't disappear because a drug is involved. Companies that come from a pharmaceutical background sometimes underestimate this side entirely, having never had to build the kind of quality infrastructure that device regulation assumes from the start.

Why Companies Underestimate This

Combination products trip up capable teams for a predictable reason: expertise tends to be lopsided. A company strong in drug development often lacks deep device experience, and a device company may have little grounding in pharmaceutical requirements, so each tends to see the product through the half it knows and undercount the half it doesn't. The result is plans built on optimistic assumptions about the unfamiliar side, timelines that don't survive contact with the real-world requirements, and evidence gaps that only surface when they're expensive to close. The complexity isn't hidden, exactly. It's just easy to miss when you're looking at it from one discipline. Investors and partners tend to spot the gap even when the team doesn't, and a plan that treats the unfamiliar half as an afterthought can undermine confidence in the whole program. Being able to speak fluently about both sides of the product, and to show a credible plan for satisfying both, is part of what separates a company that looks ready from one that merely looks hopeful.

Planning for the Complexity, Not Around It

Combination products aren't going to get simpler, because the innovation driving them is exactly what makes them valuable. The companies that bring them to market successfully are the ones that respect the complexity from the outset, classify honestly, understand which component leads, and prepare to satisfy every rulebook that applies rather than the one they find most familiar. None of this is a substitute for professional guidance tailored to a specific product, and FDA requirements are detailed and subject to change, so any company developing a combination product should work with qualified regulatory professionals who can assess its exact situation. Approached with that respect, a product that spans categories becomes a challenge to plan for rather than a trap to fall into.